Division of Hematology & Oncology, Department of Medicine, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, USA.
Curr Oncol Rep. 2020 Feb 5;22(2):15. doi: 10.1007/s11912-020-0867-2.
Oligometastatic breast cancer (OMBC) remains a poorly understood entity for which no standard of care exists at this time. This review will focus on our biologic understanding of OMBC and provide an update on current treatment strategies.
The introduction of micro RNA expression profiling has advanced our understanding of the biologic underpinnings of OMBC. Although most of the data regarding treatment have come from retrospective studies, there are now prospective randomized trials reporting progression-free survival and overall survival improvements with stereotactic ablative radiotherapy (SABR). Ongoing studies designed to evaluate addition of SABR as well as other novel agents will further develop this field and provide new treatment options. A "cure" for OMBC remains elusive. With further basic research coupled with novel prospective trials, patients will hopefully enjoy increased progression-free survival and overall survival, and ideally a delay to more toxic systemic therapy.
寡转移乳腺癌（OMBC）仍然是一个尚未被充分理解的实体，目前尚无标准的治疗方法。本综述将重点介绍我们对 OMBC 的生物学认识，并提供当前治疗策略的最新信息。
微 RNA 表达谱的引入提高了我们对 OMBC 生物学基础的理解。虽然大多数关于治疗的资料都来自回顾性研究，但现在有前瞻性随机试验报告立体定向消融放疗（SABR）可改善无进展生存期和总生存期。正在进行的旨在评估 SABR 以及其他新型药物的添加的研究将进一步发展这一领域，并提供新的治疗选择。OMBC 的“治愈”仍然难以实现。随着进一步的基础研究和新型前瞻性试验，患者有望获得更长的无进展生存期和总生存期，并理想地延迟更具毒性的全身治疗。
